P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL. (23rd June 2022) - Ghia, P.; Barnes, G.; Yang, K.; Tam, C.; Hillmen, P.; Robak, T.; Brown, J.; Kahl, B.; Tian, T.; Szeto, A.; Paik, J.; Shadman, M.